Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice

Martina Ranzenigo,1,2 Nicola Gianotti,2 Laura Galli,2 Andrea Poli,2 Andrea Mastrangelo,1,2 Elena Bruzzesi,1,2 Matteo Chiurlo,1,2 Silvia Nozza,2 Simona Bossolasco,2 Vincenzo Spagnuolo,2 Daniela Mancusi,3 Roberta Termini,3 Elisabetta Carini,2 Adriano Lazzarin,2 Antonella Castagna1,2 1Vita-Salute San R...

Full description

Bibliographic Details
Main Authors: Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A
Format: Article
Language:English
Published: Dove Medical Press 2022-06-01
Series:Drug Design, Development and Therapy
Subjects:
treatment switching
anti-retroviral agents
hiv protease inhibitors
adverse drug events
sustained virologic response
Online Access:https://www.dovepress.com/switching-from-a-non-protease-inhibitor-based-regimen-to-the-fixed-dos-peer-reviewed-fulltext-article-DDDT

Internet

https://www.dovepress.com/switching-from-a-non-protease-inhibitor-based-regimen-to-the-fixed-dos-peer-reviewed-fulltext-article-DDDT

Similar Items